Search results
Results from the WOW.Com Content Network
Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur. 2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi ...
Former research took place at the Winthrop Laboratories site near the current Fawdon Metro station, which became Sanofi, on Edgefield Avenue in Fawdon; this site made Panadol and Solpadeine. In 1978 the company wanted to open a research site at Dukes House in Hexham , on a site of 38 acres, north of the building. [ 1 ]
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of ...
The company is a wholly owned subsidiary of Sanofi group. [ 1 ] Shantha Biotechnics caters to major international markets including Asia-Pacific, Africa, Commonwealth of Independent States , and Latin America in addition to international organisations UNICEF and PAHO .
According to a statement from one of the drug's makers - France's Sanofi - the additional supply means the companies will deliver 1.4 million doses of the drug in the U.S. this year, over 25% more
Sanofi plans to advance blood cancer drugs known as anti-CD38, which include Sarclisa, despite GenMab and Johnson & Johnson's strong foothold with Darzalex in the same class.